Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage

Neurocrine Biosciences (NBIX) is considered significantly undervalued despite a recent 30% stock run-up, with an analyst reiterating a 'Buy' recommendation and projecting over 20% further share price appreciation and potential acquisition interest. The company's core assets, INGREZZA and Crenessity, are poised for strong revenue growth, supported by robust patent protection and substantial market underpenetration. Additionally, a progressing late-stage pipeline in major depressive disorder and schizophrenia offers considerable upside if clinical data proves positive, with competition for core products deemed limited in the near term.

Analysis

Neurocrine Biosciences (NBIX) presents a compelling investment case, according to the analyst, based on a combination of strong core asset performance and significant pipeline potential. The company's primary revenue drivers, INGREZZA and Crenessity, are positioned for continued growth, underpinned by robust patent protection and substantial underpenetration in their respective markets with limited near-term competitive threats. Despite a recent 30% appreciation in its share price, the stock is still considered undervalued, with the analyst projecting a further 20% or more in potential upside. This bullish outlook is further supported by a progressing late-stage pipeline, with multiple studies in major depressive disorder and schizophrenia that could add billions in value if successful. The potential for acquisition interest is also noted, with a valuation exceeding $20 billion suggested as a reasonable possibility, reinforcing the view that the company's current market capitalization does not fully reflect its intrinsic value.

Key Decisions for Investors

• Investors should evaluate Neurocrine's current valuation in the context of its dual growth drivers: the established revenue from core assets INGREZZA and Crenessity and the high-upside potential from its late-stage pipeline.
• The upcoming clinical trial readouts for major depressive disorder and schizophrenia are key catalysts that must be monitored, as positive data could significantly re-rate the stock, while negative results pose a material downside risk.
• Given the analyst's view of a >20% upside and potential M&A interest, a long position could be considered, as the stock is presented as undervalued even after its recent 30% rally.